TEL AVIV, Israel--(BUSINESS WIRE)--QuantHealth, an AI-powered clinical trial design company, today announced the formation of its inaugural Advisory Board. Founding members Michel Vounatsos, former CEO of Biogen, Rob Scott, former Chief Medical Officer for AbbVie, and Christian Hein, former VP, Global Head of Digital Transformation & Innovation Execution at Novartis, will bring their decades of pharmaceutical experience to provide strategic guidance to QuantHealth.

以色列特拉维夫——（商业新闻短讯）——人工智能驱动的临床试验设计公司QuantHealth今天宣布成立其首届咨询委员会。创始成员Biogen前首席执行官米歇尔·沃纳索斯（Michel Vounatsos）、艾伯维（AbbVie）前首席医疗官罗伯·斯科特（Rob Scott）和诺华（Novartis）前副总裁、数字转型与创新执行全球负责人克里斯蒂安·海因（Christian Hein）将带来他们数十年的制药经验，为QuantHealth提供战略指导。

The board members will help support the development and deployment of the company’s core platform services to propel the greater life sciences sector forward..

董事会成员将帮助支持公司核心平台服务的开发和部署，以推动更大的生命科学领域向前发展。。

'I’ve had a front row seat to the evolution of drug development over the past 40 years. Within those forty years, one thing has remained constant: the search to make clinical trials more affordable and predictable,” said Rob Scott, Former Chief Medical Officer at AbbVie. “I’m thrilled to play a role in reducing this burden and help the industry save time and money by partnering with some of the greatest minds in the industry – all committed to using AI to advance drug development.”.

“在过去的40年里，我一直是药物开发演变的头号人物。在这四十年里，有一件事一直保持不变：寻求使临床试验更实惠和可预测，”AbbVie前首席医疗官RobScott说。“我很高兴能在减轻这种负担方面发挥作用，并通过与业界一些最伟大的人才合作来帮助行业节省时间和金钱，这些人都致力于使用人工智能来推进药物开发。”。

90 percent of drugs in clinical development stumble before reaching the market—costing the industry a staggering $45 billion each year. QuantHealth envisions a world where clinical trial simulations and synthetic trials are an integral part of every trial's design process and regulatory path. The assembly of this advisory board underscores the company’s commitment to addressing the changing needs and challenges of the industry by democratizing data to fuel clinical trial development at-large..

临床开发中90%的药物在进入市场之前都会遇到困难，每年给该行业带来450亿美元的巨大损失。QuantHealth设想的世界是，临床试验模拟和合成试验是每个试验设计过程和监管路径的组成部分。该咨询委员会的会议强调了该公司致力于通过民主化数据来推动整个临床试验开发，以应对行业不断变化的需求和挑战。。

'The emergence of innovative tools is accelerating the pace of breakthroughs in scientific discovery like we have never seen before,” stated Christian Hein, former VP, Global Head of Digital Transformation & Innovation Execution at Novartis. “QuantHealth’s technology is a transformative force in drug R&D, especially for tackling previously unsolvable problems.

诺华前副总裁、数字转型与创新执行全球负责人克里斯蒂安·海因（ChristianHein）表示：“创新工具的出现正在加速科学发现突破的步伐，这是我们从未见过的。”。“QuantHealth的技术是药物研发领域的变革力量，特别是在解决以前无法解决的问题方面。

Their approach, in particular, has the potential to revolutionize clinical trial design, which is currently a major cost hurdle in healthcare.'.

特别是他们的方法有可能彻底改变临床试验设计，这是目前医疗保健领域的主要成本障碍。”。

QuantHealth’s dataset is trained on more than a trillion data points sourced from more than 350 million patients, 700,000 drug entities, and 180,000 clinical trials. By running tens of thousands of protocol variations, they have unlocked impressive results and have been able to predict trial outcomes with 85 percent accuracy in over 80 clinical trials, harnessing the power of AI to increase target populations, reduce study durations, reduce trial size, and improve efficacy and outcomes..

QuantHealth的数据集基于来自3.5亿多名患者，70万个药物实体和18万个临床试验的超过1万亿个数据点进行训练。通过运行数以万计的方案变化，他们已经获得了令人印象深刻的结果，并且能够在80多项临床试验中以85%的准确率预测试验结果，利用人工智能的力量来增加目标人群，缩短研究持续时间，减少试验规模，并提高疗效和结果。。

'In today's life sciences landscape, staying ahead of the curve requires not just cutting-edge products, but also a deep understanding of our customers' evolving challenges,' said Orr Inbar, CEO and Co-Founder of QuantHealth. “This collaboration will undoubtedly accelerate innovation and empower QuantHealth to strengthen our ability to anticipate the industry’s pain points to translate them into actionable solutions to share with the life sciences industry.

QuantHealth首席执行官兼联合创始人奥尔·英巴（OrrInbar）说：“在当今的生命科学领域，保持领先不仅需要尖端产品，还需要深入了解客户不断变化的挑战。”。“这种合作无疑将加速创新，并增强QuantHealth的能力，以预测行业的痛点，将其转化为可行的解决方案，与生命科学行业共享。

It is a privilege to have such a renowned team of leaders join our network.”.

有这样一支知名的领导团队加入我们的网络，我感到非常荣幸。”。

These new appointments come on the heels of QuantHealth’s appointment of Dr. Adam Petrich, MD, as the company’s first Chief Medical Officer and Adam Goldberger as Chief Financial Officer. The company also recently secured a strategic investment from Accenture Ventures and participation from a leading CRO firm and additional investors, bringing its total funding to date to $22M..

这些新任命是在QuantHealth任命AdamPetrich博士为公司首任首席医疗官和AdamGoldberger为首席财务官之后做出的。该公司最近还获得了埃森哲风险投资公司（Accenture Ventures）的战略投资，以及一家领先的CRO公司和其他投资者的参与，使其迄今为止的总资金达到2200万美元。。

About QuantHealth

关于QuantHealth

90% of drugs fail the clinical stage, representing a direct $45B annual waste to pharma companies. To address this challenge at its core, QuantHealth's Clinical-Simulator predicts how each patient in a clinical trial will respond to treatment, allowing trial design teams to predict how an entire clinical trial will play out and adapt accordingly.

90%的药物未通过临床阶段，这意味着制药公司每年直接浪费450亿美元。为了从根本上解决这一挑战，QuantHealth的临床模拟器预测了临床试验中每位患者对治疗的反应，使试验设计团队能够预测整个临床试验的结果并相应地进行调整。

Based on its novel AI engine and a vast dataset of 350m patients and over 700K therapeutics, QuantHealth's simulator can predict clinical trial results with high accuracy, allowing users to answer mission-critical questions such as trial go/no-go, cohort optimization, drug repurposing, and more. QuantHealth was founded by healthcare experts who led commercial, product, and data science at various leading companies in the US and Israel.

QuantHealth的模拟器基于其新颖的人工智能引擎和3.5亿名患者和超过7万种治疗药物的庞大数据集，可以高精度地预测临床试验结果，使用户可以回答关键任务问题，例如试验进行/不进行，队列优化，药物再利用等。QuantHealth由医疗保健专家创立，他们在美国和以色列的多家领先公司领导商业、产品和数据科学。

QuantHealth is backed by expert Life-Science investors in the US, Europe, and Israel and is supported by an advisory board of physicians and scientists from leading academic institutions. To learn more, visit https://quanthealth.ai/..

QuantHealth得到了美国、欧洲和以色列生命科学专家投资者的支持，并得到了领先学术机构医生和科学家顾问委员会的支持。要了解更多信息，请访问https://quanthealth.ai/..